Life Sciences breaking through industry
Hosted by the Milken Institute
Monday 9/12/2013 15:00-16:30

The financing gap for translational research is widening. High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. However, an industry-wide funding gap for early-stage drug development coupled with a retreat by venture investors from all but late-stage life sciences have created the need for new inventive, sustainable funding models.
In order to accelerate medical solutions, novel approaches to early-state drug and device development are needed to better manage risk, lower capital cost, and improve research effectiveness, create diverse portfolios, leverage risk-tolerant capital and access new capital sources.
In the last year, many of these approaches from novel public-private partnerships to highly leveragable venture philanthropy investments to a new breed of institutional fund managers have come into their own, with early data supporting an optimistic view of what's ahead. There is also a growing movement to apply nontraditional models as a disruptive force in biotech.
Also, important financial research supports the ideas of extending medical financing beyond corporate R&D, venture and private equity to fixed income models for longer-term financing. How are these models improving the risk-return ratio for early-stage research, making it a more attractive opportunity? What are the pitfalls? How does the involvement of philanthropic and/or government funding create leverage and attract greater private investment?
Dr. Roger Stein, Moody’s and MIT Center on Financial Engineering Dr. Leonid Bakman, Founder and Executive Director, Israel Innovation Institute
Dr. Einat Zisman,CEO, Hadasit Medical Research Services & Development.
Dr. Ora Dar, Director of Life Sciences, Office of the Chief Scientist, Ministry of Economy
Glenn Yago, Milken Institute

ההרשמה הסתימה